Trials / Completed

CompletedNCT00306566

Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients

A Phase IIa Study to Evaluate Safety, Tolerability, and Immunogenicity of a Melan-A VLP Vaccine in HLA-A2 Positive Patients With Stage II Malignant Melanoma

Status: Completed
Phase: Phase 1 / Phase 2
Study type: Interventional
Enrollment: —

Sponsor: Cytos Biotechnology AG · Industry
Sex: All
Age: 18 Years
Healthy volunteers: —

Summary

The purpose of this study is to monitor a specific cellular immune response in melanoma patients at an early stage of the disease, that have been vaccinated with a Melan-A VLP vaccine.

Conditions

Malignant Melanoma

Interventions

Type	Name	Description
BIOLOGICAL	CYT004-MelQbG10

Timeline

First posted: 2006-03-24
Last updated: 2007-09-20

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT00306566. Inclusion in this directory is not an endorsement.